Sequencing test to guide care after CD19 CAR T in kids
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study checks a DNA-based lab test (next-generation sequencing, or NGS) to monitor B-cell recovery after CD19 CAR T treatment in children and young adults. The goal is to see whether the test can help guide management while looking for remission and safe recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 1 and 25 years old when you get CD19 CAR T.
- Have CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) and a usable NGS test result (a specific DNA pattern) for monitoring.
- You received your first CD19 CAR T with a 4-1BB design within 42 days before starting the study.
- Within 42 days after CAR T, bone marrow tests must show complete remission by standard tests and be MRD-negative on either flow or NGS tracking.
- Have B-cell aplasia after CAR T for at least 42 days (very low B cells in the blood).
- You must have an identified donor for an allogeneic bone marrow transplant, and be able to complete required study tests and consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a personalized immune-cell treatment (CAR T) for adults with B-cell acute lymphoblastic leukemia (ALL) who still have tiny amounts of cancer detectable by a special test called MRD. It aims to improve outcomes for people who are in first remission but not completely “cancer-free” by MRD testing.
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
This Phase 1/2 study tests a type of immune therapy (CAR-T cells) made to recognize CD19 and CD22, two markers on B-ALL cells. It is for children and adults with B-ALL that has come back or did not respond to standard treatments, aiming to improve outcomes when other options have failed.
This trial tests a new CAR-T cell therapy for children, teens, and young adults with acute lymphoblastic leukemia that has not responded to standard treatment. The goal is to see if the therapy can put the leukemia into remission so the patient may then have a stem cell transplant.
Hear when a new B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.